Porokeratosis Market Research Report – Forecast to 2027

Porokeratosis Treatment Market Research Report: By Type ((DSAP), Linear Porokeratosis, Peoddn, Others), by Diagnosis & Treatment (Biopsy, 5-Fluorouracil, Photodynamic Therapy, Retinoids, Cryotherapy, Lasers, Others), End-User – Forecast Till 2027

ID: MRFR/Pharma/4609-HCR | February, 2021 | Region : Global

Porokeratosis Treatment Market Outlook:


Porokeratosis Treatment Market is expected to gain prominence over the forecast period. The market is expected to register a CAGR of ~6.0% from 2018 to 2023. Various factors such as rising cases of renal transplant, improved reimbursement policies in developed countries, growing research funding, and rising competition among market players are continuously contributing to the growth of the global market.   

Multiple treatment options have been suggested for porokeratosis such as medications, cryotherapy, photodynamic therapy, and lasers. Among all the treatment approaches used for the treatment of porokeratosis, laser therapy is attracting a great deal of attention. In case of malignant lesions, excision of benign lesions is often used, but it may leave scars. So, as an alternative, the CO2 laser therapy, Nd: YAG laser, and ruby laser appear to be a promising option for the treatment of porokeratosis.

Owing to the appealing aspects about laser therapy such as no incision and no hospitalization, the adoption of laser therapy for the treatment of porokeratosis is found to be rising which further drives the growth of the market.

Despite these drivers, there are some issues associated with the market. The high cost of laser systems, lack of skilled or trained physicians, side effects associated with drugs, and poor healthcare system in low and middle-income countries may hamper the growth of the market.

The porokeratosis treatment market is currently dominated by various major players. Coherent, Inc. is one of them, by holding a strong share globally. In November 2016, Coherent, Inc. acquired Rofin. Rofin is one of the world’s leading developers and manufacturers of high-performance industrial laser sources and laser-based solutions and components. Various other mergers & acquisitions have been noticed lately in the porokeratosis market. Many such developments are expected to boost the market growth.

Key Players


  • Angiodynamics, Inc. (U.S.)

  • Allergan (Republic of Ireland)

  • Alma Lasers (Israel)

  • Beiersdorf AG (Germany)

  • Biogen (U.S.)

  • Biolase Inc. (U.S.)

  • Coherent, Inc. (U.S.)

  • Coty Inc. (U.S.)

  • Cutera (U.S.)

  • Danaher Corporation (U.S.)

  • F. Hoffmann-La Roche Ltd (Switzerland)

  • Hologic Inc. (U.S.)

  • IPG Photonics Corporation (U.S.)

  • IRIDEX Corp. (U.S.)

  • L’Oreal (France)

  • Lumenis (U.S.)

  • Pfizer (U.S.)

  • PhotoMedex, Inc. (U.S.)

  • Valeant Pharmaceuticals (Canada)


Segmentation

The global porokeratosis treatment market is segmented on the basis of type of porokeratosis, diagnosis and treatment, and end-user.


By type of porokeratosis, the market is classified as Disseminated Actinic Porokeratosis (DSAP), linear porokeratosis, porokeratosis of mantoux, Porokeratotic Eccrine Ostial and Dermal Duct Nevus (PEODDN), and punctate porokeratosis.


Based on diagnosis and treatment, the market is classified as diagnosis and treatment. The diagnosis segment is further classified as biopsy, differential diagnosis, and others. The sub-segments of differential diagnosis include squamous cell carcinoma, lichenoid keratosis, and epidermal nevus. The treatment segment is further classified as topical diclofenac, ingenol mebutate, topical vitamin D analog, 5-Fluorouracil, immunomodulators, photodynamic therapy, retinoids, cryotherapy, lasers, immunosuppressive agents, and others. The sub-segments of immunomodulators include imiquimod and resiquimod. The sub-segments of retinoids include topical retinoids and oral retinoids. The sub-segments of immunosuppressive agents include calcineurin inhibitors and others.


By end-user, the market is classified as hospitals and clinics, diagnostic centers, drug stores, research and academic institutes, and others.


Geographically, the global porokeratosis treatment market has been segmented into America, Europe, Asia Pacific, and the Middle East and Africa. The American porokeratosis treatment market is further segmented into North America and South America. North America is further classified as the U.S. and Canada.


The European porokeratosis treatment market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the U.K., Italy, Spain, and the Rest of Western Europe.


The Asia Pacific porokeratosis treatment market is segmented into Japan, China, India, the Republic of Korea, Australia, and the Rest of Asia Pacific.


The Middle Eastern and African porokeratosis treatment market is segmented into the Middle East and Africa.


Regional Market Summary


Global Porokeratosis Treatment Market Share, by Region, 2017 (%)


 Porokeratosis Treatment Market Share


Source: MRFR Analysis


The Americas dominates the porokeratosis treatment market owing to the rising prevalence of disseminated superficial actinic porokeratosis and increasing renal transplant cases, as around 10.68% of renal transplant recipients suffered from porokeratosis. According to the National Kidney Foundation, Inc., in 2014, 17,107 kidney transplants took place in the U.S. Moreover, advanced diagnostic and therapeutic solutions, high healthcare expenditure, and the presence of leading players are expected to boost the American porokeratosis treatment market.


Europe holds the second position in the porokeratosis treatment market. It is expected that the rising contribution of various marketers is likely to drive the European porokeratosis treatment market. For instance, in July 2016, Chugai and Galderma announced the global license agreement for the development and marketing of Nemolizumab worldwide. The Nemolizumab is a novel biologic for skin diseases.


Asia Pacific is the fastest growing porokeratosis treatment market owing to a huge patient pool, increasing demand for treatment, and rising healthcare expenditure. In this region, the Mibelli type is most frequent as compared to other types. In Singapore, the Mibelli type of porokeratosis was present in 56% of the porokeratosis patients in 2013, suggested by a study published in the Cases in Dermatology Journal.


The Middle East and Africa holds the lowest share of the global porokeratosis treatment market due to the presence of poor and slow developing countries, especially, in the African region.


Research Methodology


Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, treatment assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on primary and secondary research.



  • Primary Research


Extensive primary research was conducted to gain a deeper insight of the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with the key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.



  • Secondary Research


Secondary research was mainly used to collect and identify information useful for an extensive, technical, market-oriented, and commercial study of the porokeratosis treatment market. It was also used to obtain key information about major players, market classification and segmentation according to industry trends, geographical markets, and developments related to the market and treatment perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, the international organization of chemical manufacturers, some paid databases, and many others.


Global Porokeratosis Treatment Market, by Type



  • Disseminated actinic porokeratosis

  • Linear porokeratosis

  • Porokeratosis of Mantoux

  • Porokeratotic Eccrine Ostial and Dermal Duct Nevus (PEODDN)

  • Punctate porokeratosis


Global Porokeratosis Treatment Market, by Diagnosis & Treatment



  • Diagnosis

  • Biopsy

  • Differential Diagnosis

  • Squamous cell carcinoma

  • Lichenoid keratosis

  • Epidermal nevus

  • Others

  • Treatment

  • Topical Diclofenac

  • Ingenol Mebutate

  • Topical Vitamin D analog

  • 3-Fluorouracil

  • Immunomodulators

  • Imiquimod

  • Resiquimod

  • Photodynamic Therapy

  • Retinoids

  • Topical retinoids

  • Oral retinoids

  • Cryotherapy

  • Lasers

  • Immunosuppressive Agents

  • Calcineurin inhibitors

  • Others

  • Others


Global Porokeratosis Treatment Market, by End-User



  • Hospitals & Clinics

  • Diagnostic Centers

  • Drug Stores

  • Research and academic institutes

  • Others


Global Porokeratosis Treatment Market, by Region



  • Americas

  • North America

  • U.S.

  • Canada

  • South America

  • Europe

  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • U.K.

  • Rest of Western Europe

  • Eastern Europe

  • Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Republic of Korea

  • Rest of Asia Pacific

  • The Middle East & Africa

  • Middle East

  • Africa


Company Profiles       



  • Angiodynamics, Inc.

  • Alma Lasers

  • Allergan

  • Beiersdorf AG

  • BIONESS, INC

  • Biogen

  • Biolase Inc.

  • Coherent, Inc.

  • COTY INC.

  • Cutera

  • Hoffmann-la Roche ltd

  • Danaher Corporation

  • HOLOGIC INC.

  • PFIZER


Intended Audience



  • Pharmaceutical Companies

  • Medical Devices Companies

  • Research and Development (R&D) Companies

  • Government Research Institutes

  • Academic Institutes and Universities

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Porokeratosis Treatment Market, by Type of Porokeratosis

6.1 Introduction

6.2 Disseminated Actinic Porokeratosis

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Linear Porokeratosis

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.4 Porokeratosis of Mantoux

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.5 Porokeratotic Eccrine Ostial and Dermal Duct Nevus (PEODDN)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.6 Punctate Porokeratosis

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Porokeratosis Treatment Market, by Diagnosis & Treatment

7.1 Introduction

7.2 Diagnosis

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.1 Biopsy

Market Estimates & Forecast, 2020–2027

7.2.2 Differential Diagnosis

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.2.1 Squamous Cell Carcinoma

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.2.2 Lichenoid Keratosis

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.2.3 Epidermal Nevus

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.3 Others

7.3 Treatment

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.1 Topical Diclofenac

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.2 Ingenol Mebutate

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.3 Topical Vitamin D Analog

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.4 3-Fluorouracil

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.5 Immunomodulators

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.5.1 Imiquimod

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.5.2 Resiquimod

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.6 Photodynamic Therapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.7 Retinoids

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.7.1 Topical retinoids

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.7.2 Oral retinoids

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.8 Cryotherapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.9 Lasers

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.10 Immunosuppressive Agents

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.10.1 Calcineurin Inhibitors

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.10.2 Others

7.3.11 Others

Chapter 8. Global Porokeratosis Treatment Market, by End-User

8.1 Introduction

8.2 Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3 Diagnostic Centers

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4 Drug Stores

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.5 Research and Academic Institutes

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.6 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 9. Global Porokeratosis Treatment Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K.

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Angiodynamics, Inc.

11.1.1 Company Overview

11.1.2 Type of Porokeratosis Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Alma Lasers

11.2.1 Company Overview

11.2.2 Type of Porokeratosis Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Allergan

11.3.1 Company Overview

11.3.2 Type of Porokeratosis Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Beiersdorf AG

11.4.1 Company Overview

11.4.2 Type of Porokeratosis/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 BIONESS, INC

11.5.1 Company Overview

11.5.2 Type of Porokeratosis Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Biogen

11.6.1 Company Overview

11.6.2 Type of Porokeratosis Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Biolase Inc.

11.7.1 Overview

11.7.2 Type of Porokeratosis Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Coherent, Inc.

11.8.1 Overview

11.8.2 Type of Porokeratosis Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 COTY INC.

11.9.1 Overview

11.9.2 Type of Porokeratosis Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Cutera

11.10.1 Overview

11.10.2 Type of Porokeratosis Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 F. Hoffmann-la Roche Ltd

11.11.1 Overview

11.11.2 Type of Porokeratosis Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 Danaher Corporation

11.12.1 Overview

11.12.2 Type of Porokeratosis Overview

11.12.3 Financials

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.13 HOLOGIC INC.

11.13.1 Overview

11.13.2 Type of Porokeratosis Overview

11.13.3 Financials

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.14 PFIZER

11.14.1 Overview

11.14.2 Type of Porokeratosis Overview

11.14.3 Financials

11.14.4 Key Developments

11.14.5 SWOT Analysis

11.15 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of the Porokeratosis Treatment Industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Porokeratosis Treatment Industry Synopsis, 2020–2027

Table 2 Porokeratosis Treatment Market Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Porokeratosis Treatment Market, by Region, 2020–2027, (USD Million)

Table 4 Porokeratosis Treatment Market, by Type of Porokeratosis, 2020–2027, (USD Million)

Table 5 Porokeratosis Treatment Market, by Diagnosis & Treatment, 2020–2027, (USD Million)

Table 6 Porokeratosis Treatment Market, by End-User, 2020–2027, (USD Million)

Table 7 North America Porokeratosis Treatment Market, by Type of Porokeratosis, 2020–2027, (USD Million)

Table 8 North America Porokeratosis Treatment Market, by Diagnosis & Treatment, 2020–2027, (USD Million)

Table 9 North America Porokeratosis Treatment Market, by End-User, 2020–2027, (USD Million)

Table 10 U.S. Porokeratosis Treatment Market, by Type of Porokeratosis, 2020–2027, (USD Million)

Table 11 U.S. Porokeratosis Treatment Market, by Diagnosis & Treatment, 2020–2027, (USD Million)

Table 12 U.S. Porokeratosis Treatment Market, by End-User, 2020–2027, (USD Million)

Table 13 Canada Porokeratosis Treatment Market, by Type of Porokeratosis, 2020–2027, (USD Million)

Table 14 Canada Porokeratosis Treatment Market, by Diagnosis & Treatment, 2020–2027, (USD Million)

Table 15 Canada Porokeratosis Treatment Market, by End-User, 2020–2027, (USD Million)

Table 16 South America Porokeratosis Treatment Market, by Type of Porokeratosis, 2020–2027, (USD Million)

Table 17 South America Porokeratosis Treatment Market, by Diagnosis & Treatment, 2020–2027, (USD Million)

Table 18 South America Porokeratosis Treatment Market, by End-User, 2020–2027, (USD Million)

Table 19 Europe Porokeratosis Treatment Market, by Type of Porokeratosis, 2020–2027, (USD Million)

Table 20 Europe Porokeratosis Treatment Market, by Diagnosis & Treatment, 2020–2027, (USD Million)

Table 21 Europe Porokeratosis Treatment Market, by End-User, 2020–2027, (USD Million)

Table 22 Western Europe Porokeratosis Treatment Market, by Type of Porokeratosis, 2020–2027, (USD Million)

Table 23 Western Europe Porokeratosis Treatment Market, by Diagnosis & Treatment, 2020–2027, (USD Million)

Table 24 Western Europe Porokeratosis Treatment Market, by End-User, 2020–2027, (USD Million)

Table 25 Eastern Europe Porokeratosis Treatment Market, by Type of Porokeratosis, 2020–2027, (USD Million)

Table 26 Eastern Europe Porokeratosis Treatment Market, by Diagnosis & Treatment, 2020–2027, (USD Million)

Table 27 Eastern Europe Porokeratosis Treatment Market, by End-User, 2020–2027, (USD Million)

Table 28 Asia Pacific Porokeratosis Treatment Market, by Type of Porokeratosis, 2020–2027, (USD Million)

Table 29 Asia Pacific Porokeratosis Treatment Market, by Diagnosis & Treatment, 2020–2027, (USD Million)

Table 30 Asia Pacific Porokeratosis Treatment Market, by End-User, 2020–2027, (USD Million)

Table 31 The Middle East & Africa Porokeratosis Treatment Market, by Type of Porokeratosis, 2020–2027, (USD Million)

Table 32 The Middle East & Africa Porokeratosis Treatment Market, by Diagnosis & Treatment, 2020–2027, (USD Million)

Table 33 The Middle East & Africa Porokeratosis Treatment Market, by End-User, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Porokeratosis Treatment Market

Figure 3 Segmentation Market Dynamics for Porokeratosis Treatment Market

Figure 4 Global Porokeratosis Treatment Market Share, by Type of Porokeratosis 2020

Figure 5 Global Porokeratosis Treatment Market Share, by Diagnosis & Treatment 2020

Figure 6 Global Porokeratosis Treatment Market Share, by End-User 2020

Figure 7 North America Porokeratosis Treatment Market Share, by Country, 2020

Figure 8 Europe Porokeratosis Treatment Market Share, by Country, 2020

Figure 9 Asia Pacific Porokeratosis Treatment Market Share, by Country, 2020

Figure 10 Middle East & Africa Porokeratosis Treatment Market Share, by Country, 2020

Figure 11 Global Porokeratosis Treatment market: Company Share Analysis, 2020 (%)

Figure 12 Angiodynamics, Inc.: Key Financials

Figure 13 Angiodynamics, Inc.: Segmental Revenue

Figure 14 Angiodynamics, Inc.: Geographical Revenue

Figure 15 Alma Lasers: Key Financials

Figure 16 Alma Lasers: Segmental Revenue

Figure 17 Alma Lasers: Geographical Revenue

Figure 18 Allergan: Key Financials

Figure 19 Allergan: Segmental Revenue

Figure 20 Allergan: Geographical Revenue

Figure 21 Beiersdorf AG: Key Financials

Figure 22 Beiersdorf AG: Segmental Revenue

Figure 23 Beiersdorf AG: Geographical Revenue

Figure 24 BIONESS, INC: Key Financials

Figure 25 BIONESS, INC: Segmental Revenue

Figure 26 BIONESS, INC Geographical Revenue

Figure 27 Biogen: Key Financials

Figure 28 Biogen: Segmental Revenue

Figure 29 Biogen: Geographical Revenue

Figure 30 BIOLASE INC.: Key Financials

Figure 31 BIOLASE INC.: Segmental Revenue

Figure 32 BIOLASE INC.: Geographical Revenue

Figure 33 COHERENT, INC.: Key Financials

Figure 34 COHERENT, INC.: Segmental Revenue

Figure 35 COHERENT, INC.: Geographical Revenue

Figure 36 COTY INC.: Key Financials

Figure 37 COTY INC.: Segmental Revenue

Figure 38 COTY INC.: Geographical Revenue

Figure 39 CUTERA: Key Financials

Figure 40 CUTERA: Segmental Revenue

Figure 41 CUTERA: Geographical Revenue

Figure 42 F. HOFFMANN-LA ROCHE LTD: Key Financials

Figure 43 F. HOFFMANN-LA ROCHE LTD: Segmental Revenue

Figure 46 F. HOFFMANN-LA ROCHE LTD: Geographical Revenue

Figure 44 DANAHER CORPORATION: Key Financials

Figure 45 DANAHER CORPORATION: Segmental Revenue

Figure 46 DANAHER CORPORATION: Geographical Revenue

Figure 47 HOLOGIC INC.: Key Financials

Figure 48 HOLOGIC INC.: Segmental Revenue

Figure 49 HOLOGIC INC.: Geographical Revenue

Figure 50 PFIZER: Key Financials

Figure 51 PFIZER: Segmental Revenue

Figure 52 PFIZER: Geographical Revenue